Evidence map›Paper›PMID 34206815›Full record

ArticleJournal of personalized medicine2021

Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer.

Ingrid Jenny Guldvik, Lina Ekseth, Amar U Kishan, Andreas Stensvold, Else Marit Inderberg, Wolfgang Lilleby

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Real world experience with [EJNMMI reports · 2024
    Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Ingrid Jenny GuldvikDepartment of Tumor Biology, Institute of Cancer Research, Oslo University Hospital, 0379 Oslo, Norway.
Lina EksethFaculty of Clinical Medicine, University of Stettin, 70-111 Szczecin, Poland.
Amar U KishanDepartment of Radiotherapy, University of California, Los Angeles, CA 90095, USA.
Andreas StensvoldDepartment of Oncology, Østfold Hospital Trust, 1714 Kalnes, Norway.
Else Marit InderbergTranslational Research Unit, Department of Cellular Therapy, Oslo University Hospital, 0379 Oslo, Norway.ORCID 0000-0002-6147-3536
Wolfgang LillebyDepartment of Oncology, Oslo University Hospital, 0379 Oslo, Norway.
Oslo University Hospital · NOØstfold Hospital Trust · NOUniversity of California, Los Angeles · USUniversity of Szczecin · PL

Funding

Magne and Bodil Foundation No number available
6 · The paper itself

Abstract

De novo metastatic or recurrence of prostate cancer (PC) remains life-threatening. Circulating tumor cells (CTCs) are noninvasive biomarkers and provide unique information that could enable tailored treatment. This study evaluated the impact of CTCs in PC patients eligible for peptide vaccine therapy. Twenty-seven patients were tested for CTCs with the CellCollector

Indexed as

biomarkercancer vaccinecirculating tumor cellsimmune responseprostate cancer

Identifiers

PMID34206815
PMCPMC8303369
OpenAlexW3174127120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.